Please login to the form below

Not currently logged in
Email:
Password:

Kevin Sin joins GSK

He becomes senior VP, head of worldwide business development

Kevin SinKevin Sin has joined GlaxoSmithKline as its senior vice president, head of worldwide business development for pharmaceutical research and development.

In this position, Sin will play a role in strengthening GSK’s pharmaceutical pipeline and identifying enabling technologies to enhance delivery of new medicines for patients.

He said: “The incredible pace of scientific and technical innovation that is happening around the world is significant and presents an abundance of opportunities to combine GSK’s strengths and capabilities with that of others to pursue big ideas in science and medicine.

“I look forward to working with the team to explore collaborations that can accelerate the discovery and development of new medicines with the potential to significantly improve human health.”

Sin joins GSK from Genetech, where he served as vice president and global head of oncology business development and has worked within the pharmaceutical and life science industry for over 20 years.

Dr Hal Barron, chief scientific officer and president of research and development, GSK, said: “I am extremely excited to have Kevin join GSK. Gaining access to the best science and technologies across the world as well as establishing highly productive collaborations with academia and industry, play an important role in creating a world-class R&D organization.

“Kevin’s leadership skills, significant expertise and successful track record make him the ideal person to lead Business Development activities for R&D.”

Sin will report to Hal Barron and will be based at the group’s San Francisco office.

1st June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics